NCT03894891View on ClinicalTrials.gov

Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 11, 2019

Primary Completion Date

October 31, 2022

Study Completion Date

December 16, 2022

Conditions
Head and Neck Cancer
Interventions
DRUG

Nivolumab

Nivolumab is a type of immunotherapy.

DRUG

Cisplatin

Cisplatin is a chemotherapy drug.

DRUG

Docetaxel

Docetaxel is a chemotherapy drug.

RADIATION

Intensity-modulated radiotherapy

IMRT is definitive treatment for head and neck cancer.

Trial Locations (4)

10029

The Tisch Cancer Institute, New York

30308

Winship Cancer Institute, Atlanta

63110

Washington University School of Medicine, St Louis

02115

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03894891 - Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer | Biotech Hunter | Biotech Hunter